摘要
类风湿性关节炎是一种常见的消耗人力,社会和经济成本相当大的慢性炎症性和破坏性关节病。它由一个综合征疼痛,滑膜的刚度和对称性炎症(滑膜炎)自由活动的关节如膝关节(动关节)组成。虽然类风湿性关节炎的病因尚不明确,本病的特点是动关节滑膜炎症,滑膜增生和炎性细胞的高潮,通过新生血管巨噬细胞和淋巴细胞。疾病修饰抗风湿药物减缓疾病的进展,并且可引起部分患者病情缓解。甲氨蝶呤是一线治疗药物,但如果患者对这种药物不能耐受,应使用生物制剂。治疗风湿性疾病的生物物质的发展一直伴随着正在进行的健康经济的讨论,这些都是非常有效的实施,但因此,高价药物是风湿性疾病的标准治疗指南。在这种方式中,必须确定更有效的策略。尽管在过去几年里,在类风湿关节炎的众多评论,这方面是在不断的发展和更新,是一个迫切需要纳入类风湿关节炎研究的新进展。本文重点强调了类风湿性关节炎目前的治疗策略的理论基础的发病机制。
关键词: 动物模型,抗风湿药,免疫病理,风湿性关节炎,治疗。
Current Medicinal Chemistry
Title:Update on Therapeutic Approaches for Rheumatoid Arthritis
Volume: 23 Issue: 21
Author(s): Eugénia Nogueira, Andreia Gomes, Ana Preto, Artur Cavaco-Paulo
Affiliation:
关键词: 动物模型,抗风湿药,免疫病理,风湿性关节炎,治疗。
摘要: Rheumatoid arthritis is a common chronic inflammatory and destructive arthropathy that consumes considerable personal, social and economic costs. It consists of a syndrome of pain, stiffness and symmetrical inflammation of the synovial membrane (synovitis) of freely moveable joints such as the knee (diarthrodial joints). Although the etiology of rheumatoid arthritis is unclear, the disease is characterized by inflammation of the synovial lining of diarthrodial joints, high synovial proliferation and an influx of inflammatory cells, macrophages and lymphocytes through angiogenic blood vessels. Diseasemodifying antirheumatic drugs slow disease progression and can induce disease remission in some patients. Methotrexate is the first line therapy, but if patients become intolerant to this drug, biologic agents should be used. The development of biological substances for the treatment of rheumatic conditions has been accompanied by ongoing health economic discussions regarding the implementation of these highly effective, but accordingly, highly priced drugs are the standard treatment guidelines of rheumatic diseases. In this way, more efficient strategies have to be identified. Despite numerous reviews in rheumatoid arthritis in the last years, this area is in constant development and updates are an urgent need to incorporate new advances in rheumatoid arthritis research. This review highlights the immunopathogenesis rationale for the current therapeutic strategies in rheumatoid arthritis.
Export Options
About this article
Cite this article as:
Eugénia Nogueira, Andreia Gomes, Ana Preto, Artur Cavaco-Paulo , Update on Therapeutic Approaches for Rheumatoid Arthritis, Current Medicinal Chemistry 2016; 23 (21) . https://dx.doi.org/10.2174/0929867323666160506125218
DOI https://dx.doi.org/10.2174/0929867323666160506125218 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Functional Impact of Alternative Splicing and Single Nucleotide Polymorphisms in Rheumatoid Arthritis
Current Pharmaceutical Biotechnology Cell Therapies for IBD: What Works?
Current Drug Targets α-Mangostin, A Natural Xanthone, Induces Apoptosis and ROS Accumulation in Human Rheumatoid Fibroblast-Like Synoviocyte MH7A Cells
Current Molecular Medicine Regulatory T-Cells: Immunomodulators in Health and Disease
Current Topics in Medicinal Chemistry Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice
Current Pharmaceutical Design Advances in Titanium-Catalyzed Synthesis of Chiral Sulfoxide Drugs
Mini-Reviews in Organic Chemistry Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals “Virostatics” as a Potential New Class of HIV Drugs
Current Pharmaceutical Design MicroRNA Therapies for Osteoarthritis and its Symptoms
Current Tissue Engineering (Discontinued) The Forward Path for Biopharmaceuticals and Biosimilars: Emerging Options in the Selection of Host Cell Systems
Current Biotechnology Lectin Techniques for Glycoproteomics
Current Proteomics Potential Therapeutic Targets for Steroid-Resistant Asthma
Current Drug Targets Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry In Vivo Target Validation: Methodology and Case Studies on the Janus Kinase Tyk2
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial [Hot Topic: Recent Advances and Future Prospect in Protease Targeting (Executive Editor: B. Turk) ]
Current Pharmaceutical Design Pre-Eclampsia: Immunological Aspects - A Role of Adhesion Molecules, Cytokines, Dendritic Cells, MHC Antigens and Auto-Antibodies
Current Women`s Health Reviews Editorial: Advances in Alzheimer Therapy: Something Old, Something New, Something Borrowed, Something Blue
Current Alzheimer Research Current and Future Pharmaceutical Therapy for Rheumatoid Arthritis
Current Pharmaceutical Design Expression of a Tagless Single-Chain Variable Fragment (scFv) of Anti-TNF-α by a Salt Inducible System and its Purification and Characterization
Protein & Peptide Letters T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design